UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41615 Mangoceuticals, Inc. (Exact name of Registrant as specified in its charter) Texas 87-3841292 (State or other jurisdiction ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number 001-41765 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 MIRA Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Florida 85-33 ...

Exhibit 99.1 Cineverse Reports First Quarter Fiscal Year 2026 Results Total Revenue of $11.1 Million, a $2.0 million or 22% Increase over Prior Year Quarter Direct Operating Margin of 57%, a 6% Improvement over Prior Year Quarter LOS ANGELES, August 14, 2025 – Cineverse Corp. ("Cineverse" or the "Company") (NASDAQ: CNVS), a global streaming technology and entertainment company, today announced its financial results for its first quarter ended June 30, 2025 ("Q1 FY 2026"): The Company's Total Revenue and Dir ...

Exhibit 99.1 Cineverse Reports First Quarter Fiscal Year 2026 Results Total Revenue of $11.1 Million, a $2.0 million or 22% Increase over Prior Year Quarter Direct Operating Margin of 57%, a 6% Improvement over Prior Year Quarter LOS ANGELES, August 14, 2025 – Cineverse Corp. ("Cineverse" or the "Company") (NASDAQ: CNVS), a global streaming technology and entertainment company, today announced its financial results for its first quarter ended June 30, 2025 ("Q1 FY 2026"): The Company's Total Revenue and Dir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ______________ Commission File Number: 001-38244 GENPREX, INC. (Exact name of registrant as specified in its charter) (State or other jur ...

收入和利润表现 - 2025年第二季度收入为321.86万美元，同比下降320.11万美元（50%）[109] - 2025年第二季度毛利润为37.51万美元，同比增长10.73万美元（40%），毛利率从4%提升至12%[110] - 2025年上半年收入为484.82万美元，同比下降818.55万美元（63%）[117] - 2025年上半年净亏损3640.23万美元，同比增加2283.47万美元（168%）[124] 成本和费用变化 - 2025年第二季度研发费用为359.83万美元，同比增加330.93万美元（超11倍）[111] - 2025年第二季度销售与营销费用为318.76万美元，同比增长98.41万美元（45%）[112] - 2025年第二季度行政费用为623.57万美元，同比增加349.75万美元（128%）[113] - 2025年第二季度股权激励成本为203.51万美元，同比增长107.67万美元（112%）[114] 现金流和财务状况 - 2025年上半年经营活动净现金流出2880.47万美元，同比增加2223.51万美元（338%）[125] - 截至2025年6月30日现金余额为6593.05万美元，存货相关余额为2099.69万美元[128] 会计准则和披露事项 - 公司已实施所有生效的新会计准则，但未对财务报表产生重大影响[143] - 公司认为除特定情况外，无其他新会计准则会对财务状况或经营结果产生重大影响[143] - 美国财务会计准则委员会(FASB)于2024年11月发布新指引，要求按类别分列经营费用的表格披露[143] - 新披露要求涵盖库存采购、员工薪酬、折旧和无形资产摊销等类别[143] - 新披露指引对公司截至2027年12月31日财年生效，可追溯适用[143] - 公司预计新指引将对合并财务报表披露产生重大影响[143] - 作为"较小报告公司"，公司无需提供市场风险的定量和定性披露[144] 公允价值计量方法 - 认股权证公允价值使用蒙特卡洛模拟模型估算，关键不可观察输入参数包括股价、行权价、无风险回报率、到期时间和波动率[142] - 不可观察输入参数的单独变动可能导致估算的公允价值发生重大增减[142]

Blaize Announces Second Quarter 2025 Financial Results Second quarter results demonstrate shift from validation to execution, with Hybrid AI and smart infrastructure deployments underway across Asia El Dorado Hills, Calif. – August 14, 2025 — Blaize Holdings, Inc. (NASDAQ: BZAI) ("Blaize"), a leader in programmable, energy-efficient edge AI computing, today announced financial results for the quarter ended June 30, 2025 – a quarter that marks a critical inflection point as Blaize shifts from technology vali ...

Exhibit 99.1 (1) NM signifies not meaningful, as the derived percentage is not meaningful to investors. Blaize Announces Second Quarter 2025 Financial Results Second quarter results demonstrate shift from validation to execution, with Hybrid AI and smart infrastructure deployments underway across Asia El Dorado Hills, Calif. – August 14, 2025 — Blaize Holdings, Inc. (NASDAQ: BZAI) ("Blaize"), a leader in programmable, energy-efficient edge AI computing, today announced financial results for the quarter ende ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to CANTOR EQUITY PARTNERS III, INC. (Exact name of registrant as specified in its charter) Cayman Islands 001-42716 98-1576549 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 001-40899 Bone Biologics Corporation (Exact name of registrant as specified in its charter) | | | (State or other juris ...